The 19S proteasome as a therapeutic target in hematologic malignancies.
- 1Department of Biological Sciences, University of Texas at El Paso, El Paso, TX, United States.
- 2Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Abstract
The ubiquitin-proteasome system (UPS) is the primary intracellular pathway for maintaining protein homeostasis through the selective degradation of ubiquitinated proteins. Central to this process is the 26S proteasome, which orchestrates the turnover of regulatory and misfolded proteins and thereby controls critical cellular functions, including cell-cycle progression, apoptosis, DNA repair, signal transduction, and stress response pathways. Dysregulation of proteasome function contributes to many hallmarks of cancer, leading to malignant transformation, disease progression, and therapeutic resistance, making the proteasome an attractive target for anticancer therapy. Clinically approved proteasome inhibitors, including bortezomib, carfilzomib, and ixazomib, have significantly improved outcomes in multiple myeloma and other hematologic malignancies by targeting the catalytic activity of the 20S core particle. However, their long-term clinical benefit is limited by intrinsic and acquired resistance and treatment-related toxicities. Recent studies have identified the 19S regulatory particle as a mechanistically distinct and therapeutically promising target. Unlike the proteolytic 20S core, the 19S complex controls substrate recognition, deubiquitination, unfolding, and translocation into the proteolytic chamber. Beyond its role in protein degradation, the 19S regulatory particle participates in transcriptional regulation, chromatin remodeling, and DNA damage responses. Several 19S subunits, particularly members of the PSMD and PSMC families, are overexpressed in hematologic and solid malignancies and are associated with poor clinical outcomes. Genetic and pharmacologic targeting of 19S ATPases and deubiquitinating enzymes induces proteotoxic stress, overcomes resistance to conventional proteasome inhibitors, and suppresses tumor growth in preclinical models. In this review, we discuss the biological functions of the 19S regulatory particle, its role in cancer pathogenesis, and emerging therapeutic strategies targeting 19S-associated proteins to improve outcomes in hematologic malignancies.
Related
- Ribosome biogenesis and selective translational control as oncogenic vulnerabilities in hematologic malignancies.
- BANF1 at the crossroads of genome stability and innate immunity: emerging implications for hematologic malignancies
- Extracellular vesicles in the immune regulation of hematological malignancies: mechanisms, prognostic significance, and therapeutic opportunities
- Hunting gremlins: GREM1 as a new therapeutic target for multiple diseases including glaucoma
- Bile Biochemistry as a Therapeutic Target in Biliary Surgery: Disease-Specific Evidence and Clinical Limits
BibTeX
@article{olivas2026proteasome,
title = {{The 19S proteasome as a therapeutic target in hematologic malignancies.}},
author = {Idaly M Olivas and Mayra A Gonzalez-Henry and Saeedeh Darvishi and Evelyn M Esparza and Anna M Eiring},
journal = {Frontiers in cell and developmental biology},
year = {2026},
month = oct,
doi = {10.3389/fcell.2026.1918833},
url = {https://europepmc.org/article/MED/42909269},
note = {CC BY},
}
RIS
TY - JOUR
TI - The 19S proteasome as a therapeutic target in hematologic malignancies.
AU - Idaly M Olivas
AU - Mayra A Gonzalez-Henry
AU - Saeedeh Darvishi
AU - Evelyn M Esparza
AU - Anna M Eiring
PY - 2026
DA - 2026/10/07
JO - Frontiers in cell and developmental biology
DO - 10.3389/fcell.2026.1918833
UR - https://europepmc.org/article/MED/42909269
AB - The ubiquitin-proteasome system (UPS) is the primary intracellular pathway for maintaining protein homeostasis through the selective degradation of ubiquitinated proteins. Central to this process is the 26S proteasome, which orchestrates the turnover of regulatory and misfolded proteins and thereby controls critical cellular functions, including cell-cycle progression, apoptosis, DNA repair, signal transduction, and stress response pathways. Dysregulation of proteasome function contributes to many hallmarks of cancer, leading to malignant transformation, disease progression, and therapeutic resistance, making the proteasome an attractive target for anticancer therapy. Clinically approved proteasome inhibitors, including bortezomib, carfilzomib, and ixazomib, have significantly improved outcomes in multiple myeloma and other hematologic malignancies by targeting the catalytic activity of the 20S core particle. However, their long-term clinical benefit is limited by intrinsic and acquired resistance and treatment-related toxicities. Recent studies have identified the 19S regulatory particle as a mechanistically distinct and therapeutically promising target. Unlike the proteolytic 20S core, the 19S complex controls substrate recognition, deubiquitination, unfolding, and translocation into the proteolytic chamber. Beyond its role in protein degradation, the 19S regulatory particle participates in transcriptional regulation, chromatin remodeling, and DNA damage responses. Several 19S subunits, particularly members of the PSMD and PSMC families, are overexpressed in hematologic and solid malignancies and are associated with poor clinical outcomes. Genetic and pharmacologic targeting of 19S ATPases and deubiquitinating enzymes induces proteotoxic stress, overcomes resistance to conventional proteasome inhibitors, and suppresses tumor growth in preclinical models. In this review, we discuss the biological functions of the 19S regulatory particle, its role in cancer pathogenesis, and emerging therapeutic strategies targeting 19S-associated proteins to improve outcomes in hematologic malignancies.
SN - 2296-634X
ER -